Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3Q9OX)

• Drug Name: Deuterated 3-cyanoquinoline derivative 1 Drug Info
• Synonyms: PMID25656651-Compound-45
• Cross-matching ID:
  PubChem CID: 76283824
  TTD Drug ID: DM3Q9OX

Molecule-Related Drug Atlas

Drug(s) Targeting Fusion protein Bcr-Abl (Bcr-Abl)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[2]
Dasatinib	DMJV2EK	Chronic myelogenous leukaemia	2A20.0	Approved	[2]
Nilotinib	DM7HXWT	Chronic myelogenous leukaemia	2A20.0	Approved	[3]
Radotinib	DMWA74Y	leukaemia	2A60-2B33	Phase 3	[4]
ABL 001	DMMF5K4	Chronic myeloid leukaemia	2A20	Phase 3	[5]
ABL001	DM7EVUF	Chronic myeloid leukaemia	2A20	Phase 3	[6]
Bafetinib	DM7586F	Bone disease	FC0Z	Phase 2	[7]
AN-019	DMJ7QP8	Chronic myelogenous leukaemia	2A20.0	Phase 2	[8]
HQP1351	DMQ30X2	Chronic myeloid leukaemia	2A20	Phase 2	[9]
NPB-001-056	DM78KMT	Chronic myelogenous leukaemia	2A20.0	Phase 1/2	[10]

Drug(s) Targeting Proto-oncogene c-Src (SRC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dasatinib	DMJV2EK	Chronic myelogenous leukaemia	2A20.0	Approved	[2]
Bosutinib	DMTI8YE	Breast cancer	2C60-2C65	Approved	[2]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[11]
Herbimycin A	DM6YWBF	Solid tumour/cancer	2A00-2F9Z	Approved	[12]
Al3818	DM3WP0N	Alveolar soft part sarcoma	2A60-2C35	Phase 3	[13]
CP-868596	DMZIM37	Gastrointestinal cancer	2C11	Phase 3	[13]
Masitinib	DMRSNEU	Amyotrophic lateral sclerosis	8B60.0	Phase 3	[14]
KX-01	DMF0NA9	Actinic keratosis	EK90.0	Phase 3	[15]
Saracatinib	DMBLHGP	Hematologic tumour	2B33.Y	Phase 2	[16]
TPX-0046	DMIVE67	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fusion protein Bcr-Abl (Bcr-Abl)	TTS7G69	BCR_HUMAN-ABL1_HUMAN	Inhibitor	[1]
Proto-oncogene c-Src (SRC)	TT6PKBN	SRC_HUMAN	Inhibitor	[1]

References

• [1] Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
• [2] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [3] 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
• [4] Danusertib, an aurora kinase inhibitor.Expert Opin Investig Drugs.2012 Mar;21(3):383-93.
• [5] ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia, NorthBuilding, 2014, 120-125.
• [6] Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019 Dec 12;381(24):2315-2326.
• [7] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [8] Design, synthesis and preclinical evaluation of NRC-AN-019. Int J Oncol. 2013 Jan;42(1):168-78.
• [9] Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors. Cell Biosci. 2019 Oct 26;9:88.
• [10] NPB001-05 inhibits Bcr-Abl kinase leading to apoptosis of imatinib-resistant cells. Front Biosci (Elite Ed). 2011 Jun 1;3:1273-88.
• [11] Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
• [12] In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells. Leuk Res. 1994 Nov;18(11):867-73.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [16] Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45.
• [17] Clinical pipeline report, company report or official report of Turning Point Therapeutics.